By Wendy Van Sickle
Columbus, Ohio, June 30 – GS Finance Corp. priced $1.07 million of autocallable contingent coupon ETF-linked notes due Sept. 30, 2021 linked to the SPDR S&P Biotech ETF, according to a 424B2 filing with the Securities and Exchange Commission.
The notes are guaranteed by Goldman Sachs Group, Inc.
The notes will pay a contingent quarterly coupon of 10.5% per annum if the ETF closes at or above its 70% coupon trigger level on the related quarterly determination date.
The notes will be called at par plus the contingent coupon plus any previously unpaid coupons if the ETF closes at or above its initial level on any quarterly determination date after six months.
The payout at maturity will be par plus the final coupon unless the ETF finishes below its coupon trigger level, in which case investors will be fully exposed to the loss of the ETF.
Goldman Sachs & Co. LLC is the agent.
| Issuer: | GS Finance Corp.
|
| Guarantor: | Goldman Sachs Group, Inc.
|
| Issue: | Autocallable contingent coupon ETF-linked notes
|
| Underlying ETF: | SPDR S&P Biotech ETF
|
| Amount: | $1,066,000
|
| Maturity: | Sept. 30, 2021
|
| Coupon: | Contingent quarterly coupon of 10.5% per annum if ETF closes at or above its coupon trigger level on the related quarterly determination date
|
| Price: | Par
|
| Payout at maturity: | Par plus the final coupon unless ETF finishes below its coupon trigger level, in which case investors will be fully exposed to the loss of the ETF
|
| Call: | At par plus the contingent coupon plus any previously unpaid coupons if ETF closes at or above its initial level on any quarterly determination date after six months
|
| Initial ETF level: | $113.75
|
| Coupon trigger: | 70% of initial level
|
| Pricing date: | June 23
|
| Settlement date: | June 26
|
| Underwriter: | Goldman Sachs & Co. LLC
|
| Fees: | 2.35%
|
| Cusip: | 40057CBM2
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
